In COVID-19 clinical update #72, Daniel Griffin covers long term symptoms in children, outcomes for MIS-C, recent guidance from the American Academy of Pediatrics, a large well traced outbreak of delta variant, low dose mRNA vaccination generates durable T cell memory and antibodies, protective immunity in recovered patients, assessment of BinaxNOW, no effect of oral azithromycin, post-discharge symptoms in Nigeria, and therapeutics for low and middle income countries.

In COVID-19 clinical update #71, Daniel Griffin reviews updated school and child care guidance from CDC, transmission in schools, accuracy of lateral flow assays, update to J&J/Janssen vaccine EUA to include GBS, interim immunogenicity of Ad.26.CoV2.s, effectiveness of mRNA vaccines to prevent hospitalization, Bamlanivimab plus Etesevimab for mild or moderate disease, and a meta-analysis of ivermectin results.

TWiV reviews evidence that COVID-19 mRNA vaccination of both uninfected and previously infected persons elicits cross-variant neutralizing antibodies, and directed evolution of a bacterial protein to form a virus-like capsid that specifically packages its encoding mRNA.

In COVID-19 clinical update #70, Daniel Griffin discusses efficacy of portable air cleaners, vaccine induced serum neutralizing antibodies against variants, prevention and attenuation of disease with mRNA vaccines, ivermectin to prevent hospitalization, IL-6 antagonists and mortality, and impact of vaccination on long COVID.

In COVID-19 clinical update #69, Daniel Griffin covers effectiveness of mRNA vaccines against the delta variant, depression among public health workers, correlates of protection against asymptomatic and symptomatic infection, BNT162b2 in ChAdOx-1-S primed individuals, prior infection rescues B and T cell responses to variants after vaccination, effect of vaccination on household transmission, germinal responses induced by mRNA vaccines, phase 3 results of Novavax vaccine, and long COVID as our next national health disaster.

In COVID-19 clinical update #68, Daniel Griffin discusses children acquiring infection at birthday parties, immunogenicity of vaccines in solid organ transplant patients, reinfection rates in recovered patients, lack of efficacy of azithromycin, bacterial and fungal infections in hospitalized patients, effect of monoclonal antibody treatment on clinical outcomes of ambulatory patients, and reduction in mortality of hospitalized patients treated with remedesivir.

In COVID-19 clinical update #67, Daniel Griffin reviews antibodies to the virus early in the US, serology testing of blood donations, MIS-C in children under 21, myocarditis in competitive athletes, ER visits for suspected suicide attempts, delta variant in Scotland, Novavax vaccine phase 3 results, vaccine coverage in pregnant women, early monoclonal administration reduces hospitalization and mortality, casirivimab and imdevimab recovery trial results, and CDC guidance on postacute sequelae.

TWiV describes how human behavior, not increased transmissibility, led to increased spread of a SARS-CoV-2 variant throughout Europe in summer 2020, and nanobodies from camelid mice and llamas that efficiently neutralize variants of concern.

In COVID-19 clinical update #66, Daniel Griffin covers treatment guidelines from IDSA, hospitalization of adolescents, estimating epidemiological dynamics from viral load distributions, incidence of infection according to baseline antibody status, assessment of reinfection in Italy, need for vaccination in previously infected individuals, assessment of protection against reinfection, antimicrobial use in hospitalized patients, effect of single dose ivermectin, and a trial of aspirin in hospitalized patients.